TNFSF10 and familial pancreatic carcinoma: Taken together, these results demonstrate that the inhibition of Gln metabolism increases the therapeutic effect of TRAIL, suggesting that this combination could be used to enhance the limited effect of TRAIL for pancreatic cancer therapy.